CBS 2019
CBSMD教育中心
English

科学研究

科研文章

荐读文献

Hypertension: Do Inflammation and Immunity Hold the Key to Solving this Epidemic? Angiographic derived endothelial shear stress: a new predictor of atherosclerotic disease progression International Study of Comparative Health Effectiveness with Medical and Invasive Approaches (ISCHEMIA) trial: Rationale and design Abnormalities in 3-Dimensional Left Ventricular Mechanics With Anthracycline Chemotherapy Are Associated With Systolic and Diastolic Dysfunction Safety of intermediate left main stenosis revascularization deferral based on fractional flow reserve and intravascular ultrasound: A systematic review and meta-regression including 908 deferred left main stenosis from 12 studies Outcomes of procedural complications in transfemoral transcatheter aortic valve replacement Empagliflozin, Health Status, and Quality of Life in Patients with Heart Failure and Preserved Ejection Fraction: The EMPEROR-Preserved Trial Guideline Update on Indications for Transcatheter Aortic Valve Implantation Based on the 2020 American College of Cardiology/American Heart Association Guidelines for Management of Valvular Heart Disease Intravascular ultrasound in the evaluation and treatment of left main coronary artery disease: a consensus statement from the European Bifurcation Club Acute Aortic Syndrome Revisited: JACC State-of-the-Art Review

Review Article2020 May 28.

JOURNAL:Heart Fail Rev. Article Link

The Management of Atrial Fibrillation in Heart Failure: An Expert Panel Consensus

D Farmakis, C Chrysohoou, G Giamouzis et al. Keywords: AF; direct oral anticoagulants; HF; non-vitamin k antagonist oral anticoagulants; rate control; rhythm control

ABSTRACT

Heart failure (HF) and atrial fibrillation (AF) often coexist, being closely interrelated as the one increases the prevalence and incidence and worsens the prognosis of the other. Their frequent coexistence raises several challenges, including under-diagnosis of HF with preserved ejection fraction in AF and of AF in HF, characterization and diagnosis of atrial cardiomyopathy, target and impact of rate control therapy on outcomes, optimal rhythm control strategy in the era of catheter ablation, HF-related thromboembolic risk and management of anticoagulation in patients with comorbidities, such as chronic kidney disease or transient renal function worsening, coronary artery disease or acute coronary syndromes, valvular or structural heart disease interventions and cancer. In the present document, derived by an expert panel meeting, we sought to focus on the above challenging issues, outlining the existing evidence and identifying gaps in knowledge that need to be addressed.